Home » Stocks » NERV

Minerva Neurosciences, Inc. (NERV)

Stock Price: $3.42 USD 0.10 (3.01%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
Market Cap 139.55M
Revenue (ttm) 41.18M
Net Income (ttm) -20.65M
Shares Out 41.92M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE 21.98
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $3.42
Previous Close $3.32
Change ($) 0.10
Change (%) 3.01%
Day's Open 3.34
Day's Range 3.19 - 3.47
Day's Volume 804,117
52-Week Range 1.81 - 15.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 weeks ago

LOS ANGELES, Feb. 8, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc....

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 8, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: N...

Newsfile Corp - 2 weeks ago

Los Angeles, California--(Newsfile Corp. - February 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerv...

Newsfile Corp - 2 weeks ago

Los Angeles, California--(Newsfile Corp. - February 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerv...

PRNewsWire - 2 weeks ago

NEW YORK, Feb. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 5, 2021) -  Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Minerva Neurosciences, Inc. (...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 4, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NA...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

Newsfile Corp - 3 weeks ago

Boston, Massachusetts--(Newsfile Corp. - February 3, 2021) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of Minerva Neurosciences, Inc. (N...

GlobeNewsWire - 3 weeks ago

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securiti...

GlobeNewsWire - 3 weeks ago

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (...

Newsfile Corp - 3 weeks ago

New York, New York--(Newsfile Corp. - February 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NA...

Newsfile Corp - 3 weeks ago

New York, New York--(Newsfile Corp. - February 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

Newsfile Corp - 3 weeks ago

New York, New York--(Newsfile Corp. - February 2, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (N...

GlobeNewsWire - 3 weeks ago

Click here to join the case

PRNewsWire - 3 weeks ago

NEW YORK, Jan. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NERV) and c...

Newsfile Corp - 3 weeks ago

New York, New York--(Newsfile Corp. - January 29, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NA...

Newsfile Corp - 3 weeks ago

New York, New York--(Newsfile Corp. - January 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

GlobeNewsWire - 3 weeks ago

BOSTON, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it has filed a class action lawsuit on behal...

GlobeNewsWire - 4 weeks ago

NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Minerva Neurosciences, Inc. (NASDAQ: NERV)  betw...

GlobeNewsWire - 4 weeks ago

NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 23, 2021) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV)...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

PRNewsWire - 1 month ago

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 20...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 21, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NA...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (N...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 20, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 20, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NA...

GlobeNewsWire - 1 month ago

NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Minerva Neurosciences, Inc. (NASDAQ: NERV)  betw...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 19, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...

Benzinga - 1 month ago

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-base...

Other stocks mentioned: ACRS, CYAD, GRTS, MRUS, TENX
Accesswire - 1 month ago

NEW YORK, NY / ACCESSWIRE / January 19, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded c...

Other stocks mentioned: BRY, OTGLY
GlobeNewsWire - 1 month ago

NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

Accesswire - 1 month ago

NEW YORK, NY / ACCESSWIRE / January 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you s...

Other stocks mentioned: BSX, KNDI
Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 16, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (N...

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and Novemb...

Accesswire - 1 month ago

NEW YORK, NY / ACCESSWIRE / January 14, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. S...

Other stocks mentioned: LRN, QIWI
Accesswire - 1 month ago

NEW YORK, NY / ACCESSWIRE / January 13, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost ...

Other stocks mentioned: BSX, SWI
Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

GlobeNewsWire - 1 month ago

NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Minerva Neurosciences, Inc. (NASDAQ: NERV)  betw...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 11, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) ...

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)-- #Minervacase--The suit alleges defendants issued false statements concerning Minerva business and prospects, resulting in its stock trading at inflated prices.

GlobeNewsWire - 1 month ago

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Minerva Neurosciences, Inc. (NASDAQ: NERV)  betw...

PRNewsWire - 1 month ago

NEW YORK, Jan. 6, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 201...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securi...

PRNewsWire - 1 month ago

LOS ANGELES, Jan. 6, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc....

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 4, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NERV)...

About NERV

Minerva Neurosciences, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form o... [Read more...]

Industry
Biotechnology
IPO Date
Jul 1, 2014
CEO
Remy Luthringer
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
NERV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for NERV stock is "Buy." The 12-month stock price forecast is 6.90, which is an increase of 101.75% from the latest price.

Price Target
$6.90
(101.75% upside)
Analyst Consensus: Buy